Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Aug 08, 2026
The Marcus Corporation (MCS): Path to $35 After Strong Gains

The Marcus Corporation (MCS): Path to $35 After Strong Gains

Key Takeaways

  • Price Target in Focus: The Marcus Corporation (NYSE: MCS) currently trades near $30.65. The $35 level represents a roughly 14% upside and sits above even the highest Wall Street analyst target of $34.
  • Strongest Bullish Factors: Robust theatre division performance, a family-friendly film slate extending through multiple quarters, market share gains versus the national box office, and potential capital return catalysts including dividend increases and share buybacks.
  • Biggest Obstacles: Elevated valuation with a trailing P/E above 41, hotel segment margin compression, a recent analyst downgrade citing limited upside, and broader consumer spending uncertainty.
  • Key Levels to Watch: The 52-week high near $32.42 serves as immediate resistance. A decisive break above that level would open the path toward $35. Support sits near the $28–$29 zone, aligned with the most conservative analyst target.
  • Bottom Line: Reaching $35 is possible but would require sustained box office outperformance, hotel segment improvement, and willingness from the market to assign an above-consensus multiple to the stock.

Why the $35 Level Matters

The $35 price level has emerged as a meaningful psychological and technical target for The Marcus Corporation. It sits just above the highest Street price target of $34, set by Wedbush in late July 2026, and represents a notable round number that often attracts trader attention. With the stock having already surged more than 135% from its 52-week low of $12.85, the question is whether MCS still has enough momentum to push through to the mid-$30s.

Company Overview

The Marcus Corporation operates two distinct business segments: movie theatres under the Marcus Theatres, Movie Tavern by Marcus, and BistroPlex brands, and a portfolio of owned and managed hotels and resorts. Headquartered in Milwaukee, the company generates the majority of its revenue from its theatres division. With a market capitalization of approximately $945 million and roughly 30.8 million shares outstanding, MCS occupies a unique niche as a diversified entertainment and hospitality operator.

Drivers That Could Support Higher Prices

The strongest case for MCS reaching $35 rests on its theatres division. The company has consistently outperformed the national box office, with attendance and per-patron spending benefiting from premium formats, higher ticket prices, and a film slate skewed toward family audiences — a demographic that also drives strong concession sales. In its most recent quarter, MCS delivered earnings of $0.51 per share, handily beating the $0.35 consensus estimate, on revenue of $231.74 million.

Several analysts have raised price targets aggressively. Wedbush boosted its target from $23 to $34, citing a "more consistent and family-focused theatrical release slate" expected to continue for multiple quarters, along with the potential for dividend increases back toward pre-pandemic levels and share repurchases. Benchmark raised its target to $33, and Barrington Research moved to $33 as well. I also checked this using Tickeron’s AI tools to see how the stock compares to others in the industry.

Additional tailwinds include the company's strong balance sheet — with no significant debt maturities until 2027 — and substantial real estate ownership that provides both asset-backing and potential monetization opportunities. Revenue is projected to grow approximately 13.6% in fiscal 2026 to $815 million, with earnings per share (EPS) expected to reach $0.66 this year and $0.84 in fiscal 2027.

Challenges That Could Limit Upside

Not all analysts share an unqualified bullish view. B. Riley downgraded MCS to Neutral from Buy in late July, raising its price target to just $29 while citing valuation concerns. The firm noted that much of the bullish scenario may already be reflected in the current stock price, leaving limited upside.

Valuation is the primary headwind. With a trailing P/E ratio above 41 and a forward P/E near 39, MCS trades at a significant premium to historical levels. The company's hotel segment has also shown margin compression, with weaker food-and-beverage and ancillary revenues raising questions about pricing power. Broader macroeconomic uncertainty — including consumer discretionary spending patterns — could pressure both theatre attendance and hotel occupancy.

Analyst Consensus and Targets

The consensus among five analysts tracked by S&P Global rates MCS as a Buy, with an average 12-month price target of $32.25. The range spans from B. Riley's $29 to Wedbush's $34. While the consensus implies only about 5% upside from current levels, the direction of recent revisions has been overwhelmingly positive: Wedbush, Benchmark, and Barrington have all raised targets significantly following the latest earnings report. A move to $35 would require the stock to trade above every current Street target — not unprecedented, but demanding continued operational momentum.

Technical Levels to Monitor

From a technical perspective, MCS is in a strong uptrend, having climbed from $12.85 to above $30 in roughly 12 months. The 52-week high of $32.42 is the most immediate resistance level; a breakout above that threshold with conviction would place $35 — the next major psychological round number — firmly within reach. On the downside, support near $28–$29 aligns with B. Riley's target and represents a zone where buyers have previously stepped in during pullbacks.

Final Assessment

The $35 target for The Marcus Corporation is ambitious but not unrealistic. It would require the stock to exceed every current Wall Street analyst price target and trade at a valuation multiple that reflects sustained earnings growth. The strongest argument for reaching that level comes from the theatres division, where market share gains, a favorable film slate, and premiumization trends continue to drive results. However, the elevated P/E ratio, hotel segment softness, and the B. Riley downgrade serve as reminders that risks remain. Investors should monitor box office trends, hotel RevPAR (revenue per available room) data, and any changes to capital allocation policy for clues about whether the path to $35 remains open.

Tickeron AI Daily Buy/Sell Signals

In my research process, I find Tickeron’s AI Daily Buy/Sell Signals particularly useful for stocks like MCS. These AI-driven signals monitor thousands of stocks and ETFs in real time, generating Buy, Sell, or Hold recommendations based on technical patterns and market shifts. They help me stay on top of momentum changes without spending hours on manual analysis.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: MCS

Contributor

<p>Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years&nbsp;developing&nbsp;his proprietary trading and quantitative algorithms (now Tickeron&rsquo;s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional,&nbsp;sophisticated stock market analysis capabilities to retail investors via&nbsp;an easy-to-use interface.</p>


MCS's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for MCS turned positive on July 22, 2026. Looking at past instances where MCS's MACD turned positive, the stock continued to rise in of 36 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 20, 2026. You may want to consider a long position or call options on MCS as a result. In of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MCS advanced for three days, in of 290 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 263 cases where MCS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 14 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MCS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

MCS broke above its upper Bollinger Band on July 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MCS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 77, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.068) is normal, around the industry mean (19.955). P/E Ratio (41.419) is within average values for comparable stocks, (106.206). Projected Growth (PEG Ratio) (2.499) is also within normal values, averaging (14.142). Dividend Yield (0.010) settles around the average of (0.016) among similar stocks. P/S Ratio (1.204) is also within normal values, averaging (2.917).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Netflix Inc. (NASDAQ:NFLX), Walt Disney Company (The) (NYSE:DIS), Roku (NASDAQ:ROKU), Paramount Skydance Corporation (NASDAQ:PSKY), AMC Entertainment Holdings (NYSE:AMC), iQIYI (NASDAQ:IQ), HUYA (NYSE:HUYA).

Industry description

Movies/entertainment industry include companies that produce and distribute motion pictures, and companies that operate general entertainment facilities like amusement parks and bowling centers. Some companies in this industry also have professional sports franchises. Live Nation Entertainment, Inc., Liberty Media Corp. and Viacom Inc. are some of the biggest companies in this space.

Market Cap

The average market capitalization across the Movies/Entertainment Industry is 17.18B. The market cap for tickers in the group ranges from 134 to 308.71B. NFLX holds the highest valuation in this group at 308.71B. The lowest valued company is LRDG at 134.

High and low price notable news

The average weekly price growth across all stocks in the Movies/Entertainment Industry was 0%. For the same Industry, the average monthly price growth was 2%, and the average quarterly price growth was 9%. CNVS experienced the highest price growth at 17%, while KWM experienced the biggest fall at -97%.

Volume

The average weekly volume growth across all stocks in the Movies/Entertainment Industry was -24%. For the same stocks of the Industry, the average monthly volume growth was -19% and the average quarterly volume growth was -53%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 63
P/E Growth Rating: 49
Price Growth Rating: 53
SMR Rating: 84
Profit Risk Rating: 76
Seasonality Score: -15 (-100 ... +100)
View a ticker or compare two or three
MCS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

an operator of hotels, resorts and movie theaters

Industry MoviesEntertainment

Profile
Details
Industry
Movies Or Entertainment
Address
100 East Wisconsin Avenue
Phone
+1 414 905-1000
Employees
7780
Web
https://www.marcuscorp.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.